Objective: To assess heterogeneity in patient and physician preferences for multiple sclerosis treatment features and outcomes via a discrete-choice experiment. Method Patients with self-reported multiple sclerosis and treating physicians participated in an online discrete-choice experiment. Patients, each considering a better or worse reference condition, and physicians, each considering two patient profiles, chose between hypothetical treatment profiles defined by seven attributes with varying levels: years until disability progression, number of relapses in the decade, mode of administration, dosing frequency, and risks of mild, moderate, and severe side effects. Latent class analysis was used to measure respondent preferences and identi...
Objectives: With an increasing number of disease-modifying treatments (DMTs) for multiple sclerosis ...
BackgroundTimely individualized treatment is essential to improving relapsing-remitting multiple scl...
Multiple sclerosis (MS) is a chronic inflammatory demyelinating neurological disorder with no known ...
Objective: To assess heterogeneity in patient and physician preferences for multiple sclerosis treat...
José Manuel Garcia-Dominguez,1 Delicias Muñoz,2 Marta Comellas,3 Irmina Gonzalbo,3 Lui...
Objectives: The aim of this study was to assess the relative importance of features of a hypothetica...
Objective. Quantitatively summarize patient preferences for European licensed relapsing-remitting mu...
Background: Multiple sclerosis (MS) is a chronic disabling, inflammatory, and degenerative disease o...
Multiple sclerosis (MS) is a chronic disabling, inflammatory, and degenerative disease of the centra...
Jinender Kumar,1 M Janelle Cambron-Mellott,2 Tom Tencer,1 Oliver Will,2 deMauri S Mackie,2 Kathleen ...
Alberto Riñon1, Mandy Buch2, Derek Holley2, Elisabetta Verdun11Merck Serono S.A. &nda...
Purpose Multidimensional unfolding is a multivariate method to assess preferences using a small sam...
Objective: To assess patients' preferences for a range of disease-modifying therapy (DMT) attributes...
grantor: University of Toronto'Purpose'. Disease-modifying drugs (DMDS) are a recent break...
BackgroundMultiple sclerosis (MS) patients are faced with complex risk-benefit profiles of disease-m...
Objectives: With an increasing number of disease-modifying treatments (DMTs) for multiple sclerosis ...
BackgroundTimely individualized treatment is essential to improving relapsing-remitting multiple scl...
Multiple sclerosis (MS) is a chronic inflammatory demyelinating neurological disorder with no known ...
Objective: To assess heterogeneity in patient and physician preferences for multiple sclerosis treat...
José Manuel Garcia-Dominguez,1 Delicias Muñoz,2 Marta Comellas,3 Irmina Gonzalbo,3 Lui...
Objectives: The aim of this study was to assess the relative importance of features of a hypothetica...
Objective. Quantitatively summarize patient preferences for European licensed relapsing-remitting mu...
Background: Multiple sclerosis (MS) is a chronic disabling, inflammatory, and degenerative disease o...
Multiple sclerosis (MS) is a chronic disabling, inflammatory, and degenerative disease of the centra...
Jinender Kumar,1 M Janelle Cambron-Mellott,2 Tom Tencer,1 Oliver Will,2 deMauri S Mackie,2 Kathleen ...
Alberto Riñon1, Mandy Buch2, Derek Holley2, Elisabetta Verdun11Merck Serono S.A. &nda...
Purpose Multidimensional unfolding is a multivariate method to assess preferences using a small sam...
Objective: To assess patients' preferences for a range of disease-modifying therapy (DMT) attributes...
grantor: University of Toronto'Purpose'. Disease-modifying drugs (DMDS) are a recent break...
BackgroundMultiple sclerosis (MS) patients are faced with complex risk-benefit profiles of disease-m...
Objectives: With an increasing number of disease-modifying treatments (DMTs) for multiple sclerosis ...
BackgroundTimely individualized treatment is essential to improving relapsing-remitting multiple scl...
Multiple sclerosis (MS) is a chronic inflammatory demyelinating neurological disorder with no known ...